NCT00116792Unknown2 期
PROVIDENCE: Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With de Novo Coronary Lesions
Gold, Herman K., MD2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2004年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 120
- 试验地点
- 2
- 主要终点
- In-stent and In-segment late lumen loss
研究概览
简要总结
We hypothesize that the combination of the thin-strut MULTI-LINK (i.e. VISION(tm) and/or MINI-VISION(tm)) stent and pharmacologic therapy with the oral PPAR-gamma agonist rosiglitazone will significantly reduce restenosis after intracoronary stenting in type 2 diabetic patients. This approach would present a more effective and economical alternative to the use of drug-eluting stents to reduce stent restenosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patients must be >18 years of age;
- •Patients must be previously diagnosed with type 2 diabetes with documented treatment with insulin, oral hypoglycemics, or diet controlled by medical history. (Undocumented or newly diagnosed diabetics must fulfill the American Diabetes Association Criteria-Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (Diabetes Care 2003;26:S5-20)).
- •Diagnosis of angina pectoris defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;
- •Treatment of lesions in native coronary arteries requiring stenting. A total of two separate lesions can be stented, located either in the same vessel (at least 10 mm or 1 cm apart) or in two separate vessels. Additional stents may be used for procedural complications such as dissections.
- •Patient is willing to comply with the specified follow-up evaluation;
- •Patient must provide written informed consent prior to the procedure using a form that is approved by the local Institutional Review Board.
- •Target lesion is ≥2.0 mm to ≤3.5mm in diameter (visual estimate);
- •Individual lesions are ≤25 mm in length located in a native coronary artery;
- •Target lesions are de novo lesions in native coronary vessels;
- •Target lesion stenosis is ≥50% and <100% (visual estimate);
排除标准
- •Patient has experienced an ST-segment elevation myocardial infarction within the preceding 24 hours.
- •Ejection fraction ≤40%; class III-IV CHF
- •Active liver disease (ALT>2.5 times upper limit of normal)
- •Woman of child-bearing potential unless demonstrated 1) negative pregnancy test and 2) clear intention of an accepted method of contraception for eight months after enrollment
- •Totally occluded vessel (TIMI 0 grade flow);
- •Impaired renal function (creatinine ≥2.5 mg/dL);
- •Target lesion involves bifurcation including a side branch ≥2.5 mm in diameter (either stenosis of both main vessel and major branch or stenosis of just major branch) that would require side branch stenting which is likely to occur if side branch is diseased and intended to be stented;
- •Previous brachytherapy of target vessel;
- •Recipient of heart transplant;
- •Patient with a life expectancy less than 12 months;
- •Known allergies to cobalt, chromium, nickel, aspirin, clopidogrel bisulfate (Plavix®) and/or ticlopidine (Ticlid®), heparin, and/or rosiglitazone (Avandia®), that cannot be medically managed;
- •Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;
- •Currently participating in an investigational drug or another device study;
- •Any contraindication to glycoprotein IIb/IIIa inhibitor therapy;
- •Current use of any TZD, i.e. rosiglitazone (Avandia®) or pioglitazone (Actos®)
- •Chronic or relapse/remitting hemolytic condition
- •Unprotected left main coronary disease with >50% stenosis;
- •Patients admitted for treatment of diabetic ketoacidosis >2 times in the past six months (brittle diabetics) and/or the suspicion of type I diabetes;
- •Target lesion is in a saphenous venous graft or internal mammary graft;
- •Target lesion is due to restenosis
- •3 vessel coronary artery disease defined as ≥70% ischemia producing lesions in 3 different epicardial coronary arteries all requiring revascularization (i.e. main left main equivalent)
结局指标
主要结局
In-stent and In-segment late lumen loss
次要结局
- Coronary artery stenosis progression in at least one non-stented lesion
- Coronary artery stenosis regression in at least one non-stented lesion
- In-stent mean percent diameter stenosis (%DS) and binary restenosis as measured by QCA at post-procedure and at 8 months
- TLR and TVR at 30 days, and 8 months post procedure
- TVF defined as cardiac death, MI, or TVR at 30 days, 8 months and l year post-procedure
- Composite of Major Adverse Cardiac Events (MACE)
- The association of metabolic factors and inflammatory indices including glycemia (HgbA1C), diabetic therapy other than TZDs, HSCRP, coagulation (PAI-1, FIB) and inflammatory marker levels (ADI, MPO, &MMP-9) with the risk for restenosis
- Target HgbA1C≤7 for all patients enrolled
- Culprit (i.e. stented artery) artery stenosis progression/regression by intravascular ultrasound (IVUS)
- (There are 3 more secondary endpoints not listed here.)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5Restenoses, CoronaryCoronary Artery DiseaseNCT05544864Deutsches Herzzentrum Muenchen376
Unknown
不适用
DCB in de Novo Coronary LesionDrug-coated BalloonNCT03691675Second Hospital of Jilin University45
已完成
不适用
Prevention of Restenosis by Concomitant Tibial artery interventions after EndoVascular Treatment in FemoroPopliteal artery diseases complicated with Poor Runoffperipheral artery diseaseJPRN-UMIN000013438Sakakibara Heart Institute200
已完成
不适用
FROST 4: Study of the Optimal Spreading of a Coronary Stent Guided With Pressure Into the Coronary ArteriesCoronary Artery InsufficiencyNCT00242892Assistance Publique - Hôpitaux de Paris800
已完成
4 期
EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal BleedingEsophageal VaricesBleedingNCT01112852National Science Council, Taiwan118